about
Use of data from multiple registries in studying biologic discontinuation: challenges and opportunitiesDiscordant inflammation and pain in early and established rheumatoid arthritis: Latent Class Analysis of Early Rheumatoid Arthritis Network and British Society for Rheumatology Biologics Register data.Ankylosing spondylitis patients commencing biologic therapy have high baseline levels of comorbidity: a report from the Australian rheumatology association database.Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis.Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics RegisterLarge-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: A systematic and critical review.Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies.Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics RegisterIntroduction/overview on clinical registries.Swedish registers to examine drug safety and clinical issues in RA.Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient registerFactors predicting pain and early discontinuation of tumour necrosis factor-α-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register.Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register.Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study SEffects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug.Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register.Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics RegisterThe comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritisOff-label use of rituximab for systemic lupus erythematosus in Europe.Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?
P2860
Q30678187-EBAF32FB-93A9-4E8D-90C4-B2555582EB44Q31148620-57A5C2D9-C03B-40C5-A287-BBEBC3D3A15BQ33602465-9A65E367-7F16-4199-854E-41B6AC06E53CQ33646340-F34E081F-72B6-4408-AD6D-6834B9C1DB67Q33692177-24E9396E-43EB-4BB3-BE56-9DCEDDECF015Q33726924-94909865-F9AB-4229-908A-1CDBED5F7404Q33858767-AD22A74D-5BDB-4E32-9EC7-657FADD68D47Q33990812-9E9B7999-1418-44DB-BC8F-BDB7C5FADDCDQ34017619-30840393-55EA-43F4-AB7C-24949CD76A89Q34623922-1514673B-E0DF-42BA-897B-97F9ACF66363Q35579447-B3167BEF-45A3-4FCB-94C3-1FCD000E17DBQ35637262-8A8A246D-EF54-45AF-8A7B-48DE61820FC0Q35637343-912812D6-37E3-47F5-B0BA-854227ADD677Q36102004-2C9DFDEE-AED1-4AFC-B2B0-10ED02DDE633Q36382724-04767B36-291A-429C-8FD1-471B12F361BAQ36633196-76C8153B-34BF-4C8D-A5C0-3E3DCF972CB2Q36725347-E4685540-053A-4536-82F0-2F4CB7F943ECQ37000109-082FF101-EB65-4C93-B48C-A426D25D11F5Q37020532-400FC7EE-DD39-4813-AE6F-696D4A114BE5Q37177593-D7AF9628-BBA0-409E-B3B6-EE5A2D3B05ADQ37206976-A0FC6A7F-0A05-4803-96F7-5056FCFC25CFQ37387224-4FAA991D-BDB7-428B-81CE-C0507A4BD21CQ39367854-A584D754-0CEE-4F0E-B4F5-FF1D6AA205E9Q47102960-1DD298EB-DE17-4FEE-87BA-DC17E99E4469
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
British Society for Rheumatology Biologics Register.
@ast
British Society for Rheumatology Biologics Register.
@en
type
label
British Society for Rheumatology Biologics Register.
@ast
British Society for Rheumatology Biologics Register.
@en
prefLabel
British Society for Rheumatology Biologics Register.
@ast
British Society for Rheumatology Biologics Register.
@en
P2093
P1476
British Society for Rheumatology Biologics Register
@en
P2093
D G I Scott
I Griffiths
P304
P356
10.1136/ARD.62.SUPPL_2.II28
P407
P478
62 Suppl 2
P577
2003-11-01T00:00:00Z